Perclose must file premarket approval (PMA) for vessel closure devices:
This article was originally published in Clinica
Perclose has been told it will have to file a PMA for its Prostar vascular closure devices, but that it will receive an expedited review. The company had previously submitted a 510(k) premarket clearance notification based on a 500-patient multicentre trial of the 9- and 11-F Prostar devices, which are used to close arteries catheterised during angioplasty. Perclose says it will use the same data for the PMA.
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.